Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

NCT00640627 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

380

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoarthritis, Knee

Interventions

DRUG: Celecoxib
DRUG: Placebo

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.